Giant Biogene Holding (SEHK:2367) Margin Compression Tests Bullish Growth Narratives

Simply Wall St.03-20

Giant Biogene Holding (SEHK:2367) has posted fresh FY 2025 numbers, with first half revenue at C¥3.1b and basic EPS at C¥1.14, setting the stage against trailing 12 month revenue of C¥6.1b and EPS of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621758504?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278","is_english":true,"pubTime":"2026-03-20 21:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621758504","market":"us","top_or_hot":-1,"title":"Giant Biogene Holding (SEHK:2367) Margin Compression Tests Bullish Growth Narratives","media":"Simply Wall St.","content":"<div>\n<p>Giant Biogene Holding (SEHK:2367) has posted fresh FY 2025 numbers, with first half revenue at C¥3.1b and basic EPS at C¥1.14, setting the stage against trailing 12 month revenue of C¥6.1b and EPS of ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/household/hkg-2367/giant-biogene-holding-shares/news/giant-biogene-holding-sehk2367-margin-compression-tests-bull\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Giant Biogene Holding (SEHK:2367) Margin Compression Tests Bullish Growth Narratives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGiant Biogene Holding (SEHK:2367) Margin Compression Tests Bullish Growth Narratives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-20 21:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/household/hkg-2367/giant-biogene-holding-shares/news/giant-biogene-holding-sehk2367-margin-compression-tests-bull><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Giant Biogene Holding (SEHK:2367) has posted fresh FY 2025 numbers, with first half revenue at C¥3.1b and basic EPS at C¥1.14, setting the stage against trailing 12 month revenue of C¥6.1b and EPS of ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/household/hkg-2367/giant-biogene-holding-shares/news/giant-biogene-holding-sehk2367-margin-compression-tests-bull\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02367","symbol_name":"巨子生物","start_time":0,"source_url":"https://simplywall.st/stocks/hk/household/hkg-2367/giant-biogene-holding-shares/news/giant-biogene-holding-sehk2367-margin-compression-tests-bull","article_id":"2621758504","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/household/hkg-2367/giant-biogene-holding-shares/news/giant-biogene-holding-sehk2367-margin-compression-tests-bull","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621758504","pubTimestamp":1774012262,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Giant Biogene Holding (SEHK:2367) has posted fresh FY 2025 numbers, with first half revenue at C¥3.1b and basic EPS at C¥1.14, setting the stage against trailing 12 month revenue of C¥6.1b and EPS of C¥2.25. The company has seen revenue move from C¥2.5b in 1H 2024 to C¥3.1b in 1H 2025, while basic EPS shifted from C¥0.99 to C¥1.14 over the same periods, providing a clear view of how the top and bottom line are tracking into the latest release. With a trailing net profit margin of 34.7% versus...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"02367":"巨子生物","BLSG":"2倍做多BLSH ETF-Leverage Shares","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","BK4112":"金融交易所和数据","BK1207":"个人用品","BLSX":"Tradr 2X Long BLSH Daily ETF"},"translate_title":"Biant Biogene Holding(SEHK：2367)利润率压缩考验看涨增长叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLSX":0.6,"BLSG":0.6,"02367":1.97},"content_text":"Giant Biogene Holding (SEHK:2367) has posted fresh FY 2025 numbers, with first half revenue at C¥3.1b and basic EPS at C¥1.14, setting the stage against trailing 12 month revenue of C¥6.1b and EPS of C¥2.25. The company has seen revenue move from C¥2.5b in 1H 2024 to C¥3.1b in 1H 2025, while basic EPS shifted from C¥0.99 to C¥1.14 over the same periods, providing a clear view of how the top and bottom line are tracking into the latest release. With a trailing net profit margin of 34.7% versus 37.2% last year, the update keeps the spotlight on how sustainably Giant Biogene can defend its profitability. See our full analysis for Giant Biogene Holding. With the headline figures on the table, the next step is to set these results against the most widely held stories about Giant Biogene to see which narratives line up with the numbers and which start to look stretched. Curious how numbers become stories that shape markets? Explore Community Narratives SEHK:2367 Earnings & Revenue History as at Mar 2026 AdvertisementTTM profit margin at 34.7% versus 37.2%  The trailing 12 month net profit margin sits at 34.7%, compared with 37.2% in the previous year, alongside trailing net income of C¥1,914.8 million on C¥5,518.5 million of revenue. What stands out for a bullish view is that a 34.7% margin is paired with reported 5 year earnings growth of 23.5% per year, yet earnings over the most recent year did not follow that multi year trend, which\n     supports the idea of a solid earnings base, while reminding bulls that the shorter term margin slip from 37.2% to 34.7% is a real data point, not just noise. highlights that anyone leaning on the 23.5% per year history should also factor in this recent margin compression when thinking about the durability of past growth.    Semi annual scale at C¥3.1b revenue and C¥1.18b profit  For 1H 2025, Giant Biogene booked C¥3,112.7 million of revenue and C¥1,182.1 million of net income (excluding extra items), compared with C¥2,540.4 million of revenue and C¥983.2 million of net income in 1H 2024. Consistent 5 year earnings growth of 23.5% per year is often cited in a bullish narrative, and these half year figures line up with that story only partially, because\n     the step up from C¥983.2 million in 1H 2024 to C¥1,182.1 million in 1H 2025 shows the business currently producing over C¥1.1b of profit every half year. at the same time, the separate note that earnings over the latest year were weaker than the 5 year trend means investors cannot simply extrapolate that 23.5% rate from these halves alone.    P/E of 15x versus peers and DCF fair value  The shares trade on a 15x trailing P/E at a price of HK$30.70, compared with a peer average of 17.6x, an Asian Personal Products industry average of 21.8x, and a DCF fair value reference point of HK$87.65. Bulls often point to the valuation gap as a key part of the case, and the numbers here heavily support that angle while also adding a few checks, because\n     the current P/E sits below both the 17.6x peer level and the 21.8x industry level, which fits the idea of a relative discount, and the DCF fair value of HK$87.65 is well above the HK$30.70 share price. yet the same data set notes that recent earnings growth lagged the 23.5% per year 5 year history and that margin has eased from 37.2% to 34.7%, so part of the discount could reflect the slower recent trajectory rather than pure mispricing.    If you want to see how this valuation picture ties into growth forecasts and risks in more detail, it is worth checking the broader community take on the stock via Curious how numbers become stories that shape markets? Explore Community Narratives Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Giant Biogene Holding's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. If the combination of strong margins, recent earnings patterns and valuation gaps leaves you curious rather than convinced, now may be a good time to look through the numbers yourself and stress test the bullish and cautious narratives side by side so you can weigh the 3 key rewards. See What Else Is Out There Margins have eased from 37.2% to 34.7% while recent earnings trends lag the 23.5% 5 year pace, suggesting profitability momentum is under some pressure. If you are concerned that softer profitability could limit the upside here, it is worth checking companies that pair resilient earnings with compelling valuations through the 228 high quality undervalued stocks.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621758504","isCrawlerRequest":true}